The Medicines Company (MDCO) : During the past 4 weeks, traders have been relatively bearish on The Medicines Company (MDCO), hence the stock is down -0.96% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -6.85% relative to the S&P 500. The 4-week change in the price of the stock is -1.49% and the stock has fallen -6.7% in the past 1 week.
The stock has recorded a 20-day Moving Average of 2.79% and the 50-Day Moving Average is 1.55%.The 200 Day SMA reached 6.71%
The Medicines Company (NASDAQ:MDCO): The stock opened in the green at $38.34 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $38.34 and a low of $37.66 for the day. The stock did not find buyers even at the lows and closed at $37.74 recording a loss of -0.97%. 980,990 shares exchanged hands during the trading day. The stock had closed at $37.74 in the previous days trading.
The Medicines Company (MDCO) : 5 investment research analysts covering The Medicines Company (MDCO) have an average price target of $51.6 for the near short term. The highest target price given by the Brokerage Firm to the stock is $65 and the lowest target is $43 for the short term. Analysts expect the variance to be within $8.65 of the average price.
The Medicines Company is a global biopharmaceutical company. The Companys marketed products are: Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Minocin (minocycline) for injection, Orbactiv (oritavancin), PreveLeak and Recothrom Thrombin topical (Recombinant). The Companys products in development include its registration stage product candidates and its research and development product candidates. It has a pipeline of acute and intensive care hospital products in development, including four registration stage product candidates for which the Company has submitted applications for regulatory approval in the United States, cangrelor, IONSYS (fentanyl iontophoretic transdermal system), Raplixa, formerly referred to as Fibrocaps, and RPX-602. The Companys four research and development product candidates include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. The Company also develops ABP-700, an intravenous anesthetic, which is in Phase I of clinical studies.